Skip to main content
Premium Trial:

Request an Annual Quote

UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer

NEW YORK – Guardant Health said Wednesday that private health insurance firm UnitedHealthcare now covers the cost of the Guardant360 CDx assay for enrolled patients who fall under the test's US Food and Drug Administration-approved companion diagnostic indications. These include individuals with advanced lung and breast cancers.

Guardant360 CDx was approved by the FDA in 2020 for comprehensive genomic profiling of all solid tumors. The assay also has a growing slate of FDA-approved CDx indications, which currently includes four targeted therapies in non-small cell lung cancer and one in advanced breast cancer.

The test has been covered for Medicare beneficiaries, regardless of tumor type or CDx indication, since 2019.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.